BioProject

Immune checkpoint inhibitor (ICI) therapies present a pillar of modern cancer therapy but can cause severe and potentially fatal neurological immune-related adverse events (n-irAEs). More...

Immune checkpoint inhibitor (ICI) therapies present a pillar of modern cancer therapy but can cause severe and potentially fatal neurological immune-related adverse events (n-irAEs). Here, we performed single-cell RNA sequencing and T cell receptor profiling of PBMCs of a cohort of 17 cancer patients receiving ICI therapy. Our data suggest alterations in regulatory T cell frequencies and B cell states, and a significant enrichment of clonally expanded CD4+ cytotoxic T lymphocytes (CD4+ CTLs) with an effector gene expression profile in n-irAE patients. Overall design: 5'scRNAseq and TCR-seq analysis of PBMCs from cancer patients with or without neurological immune adverse events (n-irAEs), before or after immume checkpoint inhibition therapy *************************************************************** Submitter states that missing raw data are being made available for controlled access in EGA. *************************************************************** Less...